




PHARMACEUTICAL 2017

CytomX Therapeutics Inc.
Rank 173 of 292





RealRate

PHARMACEUTICAL 2017

CytomX Therapeutics Inc.
Rank 173 of 292



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 48%, being 45% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	188,147
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	35,767
Liabilities, Non-Current	566
Other Assets	5,640
Other Compr. Net Income	49
Other Expenses	1,670
Other Liabilities	84,316
Other Net Income	2,356
Other Revenues	15,043
Property and Equipment	4,392
Research and Development	54,755
Selling, General and Administrative Expense	19,874

Output Variable	Value in 1000 USD
Assets	199,128
Liabilities	120,649
Expenses	76,299
Revenues	15,043
Stockholders Equity	78,479
Net Income	-58,900
Comprehensive Net Income	-58,876
Economic Capital Ratio	48%